Immunohistochemical characterization of the mTOR pathway in stage-I non-small-cell lung carcinoma

Parkin, 2001, Global cancer statistics in the year 2000, Lancet Oncol, 2, 533, 10.1016/S1470-2045(01)00486-7 Douillard, 2006, Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial, Lancet Oncol, 7, 719, 10.1016/S1470-2045(06)70804-X Wakelee, 2007, Optimal adjuvant therapy for non-small cell lung cancer – how to handle stage I disease, Oncologist, 12, 331, 10.1634/theoncologist.12-3-331 Hung, 2009, Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence, Thorax, 64, 192, 10.1136/thx.2007.094912 Hung, 2010, Prognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis, Thorax, 65, 241, 10.1136/thx.2008.110825 Zaric, 2013, Adjuvant chemotherapy and radiotherapy in the treatment of non-small cell lung cancer (NSCLC), J Thorac Dis, 5, S371 Yuan, 2000, Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer, Oncogene, 19, 2324, 10.1038/sj.onc.1203598 Lim, 2007, PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer, Oncol Rep, 17, 853 Woo, 2009, Identification of potential driver genes in human liver carcinoma by genomewide screening, Cancer Res, 69, 4059, 10.1158/0008-5472.CAN-09-0164 Pantuck, 2007, Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy, Cancer, 109, 2257, 10.1002/cncr.22677 Akcakanat, 2008, Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases, Cancer, 112, 2352, 10.1002/cncr.23456 Dhillon, 2010, Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer, J Thorac Oncol, 5, 314, 10.1097/JTO.0b013e3181ce6604 Steelman, 2004, The complexity of PTEN: mutation, marker and potential target for therapeutic intervention, Expert Opin Ther Targets, 8, 537, 10.1517/14728222.8.6.537 Wang, 2012, mTOR and PTEN expression in non-small cell lung cancer: analysis by real-time fluorescence quantitative polymerase chain reaction and immunohistochemistry, Surg Today, 42, 419, 10.1007/s00595-011-0028-1 Kaira, 2011, LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer, Am J Transl Res, 3, 468 Dobashi, 2011, Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas, Hum Pathol, 42, 214, 10.1016/j.humpath.2010.05.025 O’Byrne, 2011, Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study, Lancet Oncol, 12, 795, 10.1016/S1470-2045(11)70189-9 Oh, 2012, Clinicopathological correlations of mTOR and pAkt expression in non-small cell lung cancer, Virchows Arch, 460, 601, 10.1007/s00428-012-1239-6 Xiao, 2009, The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray, J Exp Clin Cancer Res, 28, 152, 10.1186/1756-9966-28-152 Chan, 2004, Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer, Br J Cancer, 91, 1420, 10.1038/sj.bjc.6602162 Cappuzzo, 2004, Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer, J Natl Cancer Inst, 96, 1133, 10.1093/jnci/djh217 Massion, 2004, Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression, Am J Respir Crit Care Med, 170, 1088, 10.1164/rccm.200404-487OC Bose, 2006, The Akt pathway in human breast cancer: a tissue-array-based analysis, Mod Pathol, 19, 238, 10.1038/modpathol.3800525 Panigrahi, 2004, The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome, J Pathol, 204, 93, 10.1002/path.1611 Yoshizawa, 2010, Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer, Clin Cancer Res, 16, 240, 10.1158/1078-0432.CCR-09-0986 Munari, 2013, Dysregulation of mammalian target of rapamycin pathway in upper tract urothelial carcinoma, Hum Pathol, 44, 2668, 10.1016/j.humpath.2013.07.008